Press release
High-Grade Glioma Market is expected to reach USD 9.92 billion by 2034
High-Grade Glioma
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70861
The next decade will see accelerated research in precision oncology, immunotherapy, tumor-treating fields (TTF) technology, and next-generation imaging, aiming to improve survival rates and patient quality of life. Increased clinical trial activity and advancements in molecular diagnostics will be critical growth drivers.
Market Overview
• Market Size (2024): USD 5.28 billion
• Forecasted Market Size (2034): USD 9.92 billion
• CAGR (2024-2034): ~6.5%
• Key Drivers: Advances in molecular profiling, increased R&D for targeted therapies, and improved surgical and radiotherapy techniques.
• Challenges: High recurrence rates, limited drug penetration across the blood-brain barrier (BBB), and treatment resistance.
• Leading Players: F. Hoffmann-La Roche Ltd., Novocure Ltd., Merck & Co., Bristol Myers Squibb, Pfizer Inc., Amgen Inc., and Denovo Biopharma.
Segmentation Analysis
By Tumor Type
• Anaplastic Astrocytoma (Grade III)
• Anaplastic Oligodendroglioma (Grade III)
• Glioblastoma Multiforme (Grade IV)
By Treatment Type
• Surgery
• Radiation Therapy
• Chemotherapy (Temozolomide, Carmustine)
• Targeted Therapy (VEGF inhibitors, EGFR inhibitors)
• Immunotherapy (PD-1/PD-L1 inhibitors, CAR-T therapy)
• Tumor Treating Fields (TTF)
By End Use
• Hospitals & Cancer Centers
• Specialty Clinics
• Academic & Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary
While surgery and chemoradiation remain the standard, targeted therapies, immuno-oncology agents, and TTF devices are increasingly incorporated into treatment protocols for recurrent and advanced HGG.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70861/high-grade-glioma-market
Regional Analysis
North America
• Holds ~46% of market share in 2024.
• Strong adoption of TTF devices and targeted therapies.
• Robust clinical trial ecosystem.
Europe
• EMA-approved innovative therapies driving adoption in major markets like Germany, France, and the UK.
Asia-Pacific
• Fastest-growing region (CAGR > 8%).
• Increasing healthcare investment in China, Japan, and South Korea.
• Expansion of neurosurgical facilities.
Middle East & Africa
• GCC countries leading with improved access to neuro-oncology treatments.
Latin America
• Brazil and Argentina expanding specialized cancer centers.
Regional Summary
North America dominates the market due to advanced healthcare infrastructure, but Asia-Pacific will experience the highest growth due to rising diagnosis rates and healthcare modernization.
Market Dynamics
Key Growth Drivers
1. Rising incidence of brain tumors in aging populations.
2. Precision medicine adoption with genetic and molecular profiling.
3. Regulatory incentives for orphan drug development.
4. Integration of TTF technology into treatment protocols.
Key Challenges
1. High relapse rates despite aggressive treatment.
2. Limited BBB-penetrating therapies.
3. High treatment costs impacting accessibility in developing nations.
4. Neurocognitive side effects from prolonged therapy.
Latest Trends
• Liquid biopsy research for early relapse detection.
• Combination therapy trials (immunotherapy + radiotherapy).
• AI-assisted neuroimaging for early diagnosis.
• Development of next-gen TTF devices for better compliance.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70861
Competitor Analysis
Major Players
• F. Hoffmann-La Roche Ltd. (Avastin® - Bevacizumab)
• Novocure Ltd. (Optune® - Tumor Treating Fields)
• Merck & Co., Inc. (Keytruda® - Pembrolizumab)
• Bristol Myers Squibb (Opdivo® - Nivolumab)
• Pfizer Inc.
• Amgen Inc.
• Denovo Biopharma
• Kintara Therapeutics, Inc.
• Celldex Therapeutics
• ImmunoCellular Therapeutics Ltd.
• DNAtrix Inc.
• Tocagen Inc.
• VBL Therapeutics
• Ziopharm Oncology, Inc.
Competitive Summary
The HGG market is highly research-focused, with companies pursuing BBB-penetrating drugs, combination regimens, and device-based therapies to extend survival.
Conclusion
The high-grade glioma market is poised for transformational growth as precision oncology, immunotherapy, and device-based interventions converge. By 2034, innovations in drug delivery, imaging, and tumor biology understanding will redefine patient outcomes.
Key opportunities include:
• Developing next-gen targeted agents with improved BBB penetration.
• Scaling access to TTF devices in emerging markets.
• Integrating AI-powered imaging for early detection and personalized treatment.
This report is also available in the following languages : Japanese (高悪性度神経膠腫市場), Korean (고등급 신경교종 시장), Chinese (高级别胶质瘤市场), French (Marché du gliome de haut grade), German (Markt für hochgradige Gliome), and Italian (Mercato del glioma di alto grado), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70861/high-grade-glioma-market#request-a-sample
Our More Reports:
Frontotemporal Dementia Market
https://exactitudeconsultancy.com/reports/70788/frontotemporal-dementia-market
Anesthetic Effect Market
https://exactitudeconsultancy.com/reports/70790/anesthetic-effect-market
Chronic Neuropathic Pain Market
https://exactitudeconsultancy.com/reports/70792/chronic-neuropathic-pain-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High-Grade Glioma Market is expected to reach USD 9.92 billion by 2034 here
News-ID: 4143990 • Views: …
More Releases from Exactitude Consultancy
Relapsed/Refractory Acute Myeloid Leukemia Market is expected to reach USD 6.1 b …
Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. Despite advances in frontline therapies, relapse is common, and many patients develop refractory disease, leaving limited treatment options and poor survival outcomes. Relapsed/refractory AML (R/R AML) remains a major unmet clinical need.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71571
In recent years, however, the…
Retinoblastoma Market to Reach USD 1.2 Billion by 2034
Retinoblastoma is a rare pediatric eye cancer that originates in the retina and primarily affects children under five years of age. It accounts for around 3% of all childhood cancers but is the most common intraocular malignancy in children. With improved awareness, early screening, and advances in treatment, survival rates in developed nations exceed 90%. However, challenges remain in low- and middle-income countries where delayed diagnosis and limited access to…
Severe Toxicities in Lymphoma Market Projected to Reach USD 3.7 Billion by 2034
Lymphoma, a group of blood cancers affecting the lymphatic system, is broadly classified into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). While survival outcomes have improved significantly with chemotherapy, radiotherapy, targeted agents, and immunotherapies, many patients experience severe toxicities as side effects of treatment. These toxicities - ranging from cytokine release syndrome (CRS) and neurotoxicity in CAR-T therapy to myelosuppression, infections, and organ toxicities from chemotherapy and immunomodulators - can…
Soft Tissue Neoplasms Market to Reach USD 6.0 Billion by 2034
Soft tissue neoplasms are abnormal growths arising from connective tissues, including muscles, fat, nerves, tendons, and blood vessels. While some are benign, malignant forms such as soft tissue sarcomas (STS) pose serious clinical challenges due to their aggressive nature, rarity, and diverse histological subtypes. Representing about 1% of all adult cancers, these neoplasms require a wide spectrum of treatments ranging from surgery and radiotherapy to chemotherapy and novel targeted therapies.
Download…
More Releases for TTF
Recurrent Malignant Glioma Market Expected to Hit USD 4.0 Billion by 2034
Gliomas are the most common malignant brain tumors, arising from glial cells in the central nervous system. While initial treatment usually involves surgery, radiotherapy, and chemotherapy, recurrence is frequent, and outcomes remain poor. Recurrent malignant gliomas (rMG), including glioblastomas and anaplastic astrocytomas, represent one of the most challenging areas in oncology, with limited treatment options and median survival often less than a year.
Download Full PDF Sample Copy of Market Report…
TTF Mumbai 2025 Wraps Up on a High Note, Rekindling Travel Trade Momentum in the …
Mumbai, 19th August - The much-anticipated, exclusively B2B TTF Mumbai 2025 concluded today, marking a strong return of India's leading travel trade show to the country's financial capital. Held from 11 to 13 August at the Jio World Convention Centre (JWCC), the event brought together over 9,000 travel trade professionals and 500+ exhibitors, reaffirming Mumbai's role as a vital hub in India's travel ecosystem. With the Diwali travel season approaching,…
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2 …
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural lining of the lungs, most often caused by prolonged asbestos exposure. It is associated with a poor prognosis due to late-stage diagnosis and limited curative options. Traditionally treated with surgery, chemotherapy, and radiation, the MPM market is undergoing transformation as immunotherapy, targeted agents, and advanced imaging gain traction.
Download Full PDF Sample Copy of Market Report…
Glioblastoma Multiforme Market to Reach USD 6.91 Billion by 2034
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adults, accounting for nearly 50% of malignant brain tumors. Despite advances in surgery, radiotherapy, and chemotherapy, median survival remains just 12-18 months due to tumor heterogeneity, rapid progression, and high recurrence rates.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70857
The next decade is expected to see significant changes in GBM treatment strategies, with novel…
Drone Motors Market 2019 Future Technological Advancement and Phenomenal Growth …
Drone Motors Market is a detailed research study that provides answers and pertinent questions with respect to the emerging trends and growth opportunities in this industry. It helps identify each of the prominent barriers to growth, apart from identifying the trends within various application segments of the Global market for Drone Motors. Collecting historical and recent data from various authentic resources and depending on all the factors and trends, the…
Drone Motors Market Evolving Technology Trends and Industry Analysis by Top Key …
Drone Motors Market 2019 comprehensive research report includes a brief on these trends that can help the businesses operating in the industry to understand the market and strategize for their business expansion accordingly. The research report analyzes the market size, industry share, growth, key segments, CAGR and key drivers.
Get Sample Copy of this Report - https://www.orianresearch.com/request-sample/819988
The Global Drone Motors market 2019 research provides a basic overview of the…
